MAPK8 and neoplasm: We found that patients with tumours that had mutations in JNK pathway genes had the most favourable OS (median survival = 141.7 months) and DFS (undefined median DFS) outcomes, a finding that is consistent with other studies that have shown an association between alterations in JNK pathway genes and both enhanced apoptosis37–39 and improved survival outcomes37,38,40 (Fig. 2f, g).